For the first time, precision medicine allows patients to be divided into genetically defined sub-populations. Our precision medicine approach will allow physicians to identify and treat patients with a therapeutic that is specific to their genetic identity.
Evolution of Precision Medicine
In the 20th century, the concept of precision medicine evolved to address the rise in the number of blood transfusions and the need to identify individuals in different blood groups. Data about blood donors and recipients led to a better understanding of how genetics relates to blood types and how diseases pass from generation to generation.
In the 21st century, the Human Genome Project has expanded our knowledge of the link between an individual’s genetic makeup and their health. Armed with this knowledge, scientists have developed genetic maps which inform why one individual responds differently from another to the same treatment. For example, greater understanding of genetics has led to the approval of precision medicines to target sub-populations of patients suffering from specific types of cancers and specific variants in the cystic fibrosis gene.
Precision Medicine in AMD and Linked Diseases
Gemini Therapeutics is leveraging the proven principles of precision medicine to advance the evaluation and treatment of complex retinal diseases affecting millions of people. In the same way that oncologists can now treat the subset of patients who have PD-L1 positive non-small-cell lung cancer, we are applying our insights into genetically defined sub-populations of AMD and linked diseases. Our pioneering development of precision medicines in these diseases can transform the lives of patient sub-populations with high clinical need and no therapeutic options.
Insights from our work on genetic risk factors and understanding of those risks at the molecular level has led us to modulation of the innate immune system and the complement pathway and its role in dry AMD.
While other efforts have largely focused on blocking the complement system, Gemini Therapeutics is developing a new class of therapeutics to restore regulation of the complement system. We are advancing our drug candidates and selection of patients based on what we’ve learned about the genetics of patients with dry AMD.